LA JOLLA PHARMACEUTICAL CO: 10-Q filed 2011-11-14

Name: LA JOLLA PHARMACEUTICAL CO: 10-Q filed 2011-11-14
Creator: LA JOLLA PHARMACEUTICAL CO

What LA JOLLA PHARMACEUTICAL CO reported in its quarterly report filed 2011-11-14 (fiscal Q3 2011): 22 published measures, 62 facts as tagged in accession 0000950123-11-097820.

This filing

Form: 10-Q (quarterly report)
Filed: 2011-11-14
Fiscal period: fiscal Q3 2011
Accession: 0000950123-11-097820 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All LA JOLLA PHARMACEUTICAL CO filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2011-09-30	5,511,000	USD
At 2010-12-31	6,933,000	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2011-09-30	-2,258,000	USD
At 2010-12-31	482,000	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2011-09-30	5,502,000	USD
At 2010-12-31	6,866,000	USD
At 2010-09-30	7,272,000	USD
At 2009-12-31	4,254,000	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2011-07-01 to 2011-09-30	3,570,000	USD	92
2011-01-01 to 2011-09-30	1,775,000	USD	273
2010-07-01 to 2010-09-30	-222,000	USD	92
2010-01-01 to 2010-09-30	-5,093,000	USD	273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2011-01-01 to 2011-09-30	-1,364,000	USD	273
2010-01-01 to 2010-09-30	-2,985,000	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2010-01-01 to 2010-09-30	6,003,000	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2011-09-30	-426,306,000	USD
At 2010-12-31	-428,081,000	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2011-07-01 to 2011-09-30	53,341,000	shares	92
2011-01-01 to 2011-09-30	22,418,000	shares	273
2010-07-01 to 2010-09-30	947,000	shares	92
2010-01-01 to 2010-09-30	793,000	shares	273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2011-07-01 to 2011-09-30	1,288,000,000	shares	92
2011-01-01 to 2011-09-30	4,869,581,000	shares	273
2010-07-01 to 2010-09-30	947,000	shares	92
2010-01-01 to 2010-09-30	793,000	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2011-07-01 to 2011-09-30	0.07	USD/shares	92
2011-01-01 to 2011-09-30	0.08	USD/shares	273
2010-07-01 to 2010-09-30	-0.49	USD/shares	92
2010-01-01 to 2010-09-30	-6.84	USD/shares	273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2011-07-01 to 2011-09-30	0	USD/shares	92
2011-01-01 to 2011-09-30	0	USD/shares	273
2010-07-01 to 2010-09-30	-0.49	USD/shares	92
2010-01-01 to 2010-09-30	-6.84	USD/shares	273

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2011-01-01 to 2011-09-30	194,000	USD	273
2010-01-01 to 2010-09-30	402,000	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2011-07-01 to 2011-09-30	-423,000	USD	92
2011-01-01 to 2011-09-30	-1,805,000	USD	273
2010-07-01 to 2010-09-30	-702,000	USD	92
2010-01-01 to 2010-09-30	-3,379,000	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2011-09-30	5,511,000	USD
At 2010-12-31	6,933,000	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2011-09-30	2,629,000	USD
At 2010-12-31	6,404,000	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2011-09-30	23,000	USD
At 2010-12-31	39,000	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2011-01-01 to 2011-09-30	177,000	USD	273
2010-07-01 to 2010-09-30	4,000	USD	92
2010-01-01 to 2010-09-30	13,000	USD	273

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2011-09-30	151,000	USD
At 2010-12-31	178,000	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2011-09-30	9,000	USD
At 2010-12-31	67,000	USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2011-07-01 to 2011-09-30	3,567,000	USD	92
2011-01-01 to 2011-09-30	1,850,000	USD	273
2010-07-01 to 2010-09-30	-469,000	USD	92
2010-01-01 to 2010-09-30	-5,427,000	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2011-07-01 to 2011-09-30	423,000	USD	92
2011-01-01 to 2011-09-30	1,628,000	USD	273
2010-07-01 to 2010-09-30	698,000	USD	92
2010-01-01 to 2010-09-30	3,366,000	USD	273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2011-01-01 to 2011-09-30	234,000	USD	273
2010-01-01 to 2010-09-30	-1,000	USD	273

Inspect the source

Entity: LA JOLLA PHARMACEUTICAL CO / CIK 0000920465
Captured: 2026-09-22 19:35 UTC
SEC response SHA-256: b3ec81ce285251633cde90653d8efd46d4d3a89d0ccad4d0a2cf011b8bc868fa

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000920465.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))